TABLE 1.

Characteristics of Patients With PTCL in First Complete Remission

Characteristic	Non-ASCT (n = 83)	ASCT (n = 36)	P
Age
<65 y, No. (%)	39 (47)	23 (64)	.09
≥65 y, No. (%)	44 (53)	13 (36)
Mean ± SD, y	64.5 ± 13.9	57.5 ± 12.6
Range, y	24–89	23–75
Sex, No. (%)
Female	28 (34)	8 (22)	.21
Male	55 (66)	28 (78)
Race, No. (%)
White	65 (78)	30 (83)	.32
Black	11 (13)	4 (11)
Asian	3 (4)	0
Other/unavailable	4 (5)	2 (6)
ECOG performance status, No. (%)
0–1	79 (95)	35 (97)	.61
2	4 (5)	1 (3)
3	0	0
Histologic subtype, No. (%)
AITL	18 (22)	17 (47)	.01
ALK-negative ALCL	26 (31)	4 (11)	.02
PTCL NOS	39 (47)	15 (42)	.59
Ann Arbor stage, No. (%)
I/II	30 (36)	3 (8)	.01
III/IV	53 (64)	33 (92)
Bone marrow involvement, n/N (%)	11/40 (28)	8/13 (62)	.03
IPI score, No. (%)
0–2	59 (71)	23 (64)	.44
3–4	24 (29)	13 (36)
PIT score, No. (%)
1	18 (22)	9 (25)	.23
2	38 (46)	15 (42)
3	22 (27)	6 (17)
4	5 (6)	6 (17)
First-line chemotherapy
Anthracycline-containing, No. (%)	54 (71)	25 (71)	.97
No. of cycles, mean ± SD	4.8 ± 2.3	4.9 ± 1.9	.71

Abbreviations: AITL, angioimmunoblastic T-cell lymphoma; ALCL, anaplastic large cell lymphoma; ALK, anaplastic lymphoma kinase; ASCT, autologous stem cell transplantation; ECOG, Eastern Cooperative Oncology Group; IPI, International Prognostic Index; NOS, not otherwise specified; PIT, Prognostic Index for PTCL; PTCL, peripheral T-cell lymphoma; SD, standard deviation.

Sums may exceed 100% because of rounding.